Overview

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Forward Pharmaceuticals Co., Ltd.
Collaborator:
WuXi Clinical